Individuals practice these CGFNS Latest Questions to get 100 percent marks offers 100 percent free practice exam for attempts before purchase. We are certain that you will fulfill the nature of CGFNS Latest Questions with actual test questions that we give. Simply register for complete Commission on Graduates of Foreign Nursing Schools questions bank and download your duplicate. Download VCE tests test system for training and you will feel certain before you face a genuine CGFNS test.

Exam Code: CGFNS Practice test 2022 by team
CGFNS Commission on Graduates of Foreign Nursing Schools

Exam : CGFNS
Exam Name : Commission on Graduates of Foreign Nursing Schools
Exam Type : MCQ
Questions : 260
Part1 Questions : 150
Part1 test Time : 2 hrs 30 min.
Break : 1 hour
Part2 Questions : 110
Part2 test Time : 1 hr 50 min.

The CGFNS Certification Program® is a three part program that consists of:
1. A credentials evaluation of secondary education, nursing education and licensure
2. The CGFNS Qualifying Exam®
3. Demonstration of passing one of the accepted English language proficiency examinations
It is a requirement for licensure by some State Boards of Nursing to take the NCLEX-RN® exam.

First-level, general nurses educated outside the United States who wish to practice nursing in the United States use this service. A first-level, general nurse (as defined historically by the International Council of Nurses) is also called a registered (RN) or a professional nurse in some countries.

Second-level nurses are not eligible to be licensed as registered nurses in the United States and therefore cannot be approved to take the CGFNS Qualifying Exam®. A second-level nurse may be called an enrolled, vocational or practical nurse or a nurse assistant.

The CGFNS test has both Nursing section. The CGFNS test is a multiple choice and objective based paper. It is divided into two parts with a total of 260 questions. Candidates should submit anyone TOEFL, TOIEC or IELTS scores for an eligibility criterion.
Applicants are given 150 questions in the part 1 test with a time limit of 2 hours and 30 minutes. You will get a 1 hour break for lunch after you are done with part 1 section. The part 2 section contains 110 questions with a time limit of 1 hours and 50 minutes.
The candidates must demonstrate English language proficiency and they should be able to get the passing scores for that. Any of the English proficiency test has three parts, listening, and vocabulary and sentence structure.
It takes more than 4 hours for its completion. It is taken by experienced people and thus it covers various critical areas. Like maternal or infant nursing, child care and mental health subjects. Read on to know more information on CGFNS test.

The program is comprised of three parts: a credentials review, which includes an evaluation of the secondary and nursing education, registration and licensure; the CGFNS International Qualifying test SM.
It tests nursing knowledge and is administered 3–4 times per year in over 50 locations worldwide (if applicant base warrants);and an English language proficiency examination.

Commission on Graduates of Foreign Nursing Schools
Medical Commission PDF Download
Killexams : Medical Commission PDF get - BingNews Search results Killexams : Medical Commission PDF get - BingNews Killexams : PMC issues 7,290 licenses to doctors in 30 days
PMC issues 7,290 licenses to doctors in 30 days
PMC issues 7,290 licenses to doctors in 30 days

ISLAMABAD: The Pakistan Medical Commission (PMC) has issued 7,290 renewals and licenses within a period of 30 days to medical practitioners. According to PMC, the Commission also issued some 1,085 good standing certificates out of received 1,801 requests.

The PMC successfully made registration of 454 faculty members, besides 338 post-graduate clinical qualifications out of 485 requests. Likewise, 110 foreign graduates were registered against 186 applications.

PMC President Dr Noshad Ahmad Shaikh, in a statement, said the Commission’s priority was to facilitate doctors, students and other stakeholders in the larger national interest. He warned that negligence of any sort would not be tolerated in that regard.

The new PMC council after assuming the charge has started working for doctors, students and relevant stakeholders and also taken all necessary steps to resolve their genuine and relevant pertaining issues.

Wed, 12 Oct 2022 04:33:00 -0500 en-US text/html
Killexams : Baraboo agrees to form joint emergency district

If the other four potential members of the proposed Baraboo Area Joint Fire and Emergency Medical Services District unanimously approve a draft intergovernmental agreement and bylaws as Baraboo City Council members did Tuesday, local fire and ambulance services will be combined.

Ald. Joel Petty, who serves on the Baraboo Ambulance Commission and as the chairperson of the committee formed to consolidate the two departments, said there has been a multistep process to arrive at a tentative final agreement.

“Throughout the course of that there were a number of different drafts, a number of different reviews,” Petty said. “It’s extremely thorough.”

It could be a fluid document depending on how other communities want to proceed, Petty said.

“I don’t really know if there is a final document because this is a document that potentially could be amended down the road,” Petty said.

People are also reading…

The intergovernmental agreement combines the Baraboo District Ambulance Service and the Baraboo Fire Department into one entity. With this change, personnel will share space as they have been for roughly a year and will likely cross-train personnel to respond to all kinds of emergencies.

The city of Baraboo, the village of West Baraboo and the towns of Baraboo, Fairfield and Greenfield will be members of the joint district. The new district cannot be realized until each of the potential members approves of an identical intergovernmental agreement.

The Baraboo District Ambulance Service had seven municipal members. With this change, the towns of Excelsior and Sumpter will no longer receive services from them after declining to become members of the joint district.

A new commission will be formed to oversee the district. Each member municipality has representation on the commission. Mayor Rob Nelson pointed to the consolidation change as a shift in the power dynamic as well. There will be four votes from the city of Baraboo. Because passage of any measure requires at least six votes out of a total of eight, more than one municipality would need to agree with Baraboo.

“The city does cede a little bit of authority in this agreement,” Nelson said. “The city won’t be able to do anything on its own; the townships or the village won’t be able to do anything on their own. Any significant change is going to require six of those eight members to reach a consensus.”

A personnel board will oversee employment for the district, from hiring and firing to disciplinary actions, much like the Baraboo Police and Fire Commission does for the city.

If a municipality declined to be part of the combined fire and ambulance district, it could still enter into a contract with the commission for one or both of its services.

Baraboo has also been planning new facilities for emergency personnel. There are currently plans underway to build one or two new stations within Baraboo. Discussion about the buildings has evolved to consideration of having two buildings rather than one: one main station and a satellite station, each on an opposite side of the city.

City officials have said they are hopeful to be able to begin construction in 2024.

Ald. Jason Kent expressed concerns over budget plans laid out in the intergovernmental plan, specifically that there may need to be more policy outlined in the contract, but said the current outline is manageable and supported moving forward.

“There have been a number of lawyers who have been looking at this, so I don’t think this is final,” Kent said. “But I think this is the initial starting point to get this district in place.”

Follow Bridget on Twitter @cookebridget or contact her at 608-745-3513.

Wed, 12 Oct 2022 09:34:00 -0500 en text/html
Killexams : MBBS, BDS Admissions 2022: KNRUHS begins registrations, check out eligibility, application process, details here

Telangana: Kaloji Narayana Rao University of Health Sciences (KNRUHS) has released the prospectus for admission into MBBS & BDS courses under the competent authority quota for the academic year 2022-2023.

Important dates –

Availability of online Application and uploading of certificates

10.00 A.M. on 11-10-2022 to

6.00 P.M. on 18-10-2022

Date of release of provisional final merit list after verification of certificates

To be notified later.

Dates of exercising web options for admission into MBBS/BDS

courses counselling.

To be notified later.

Commencement of classes.

To be notified later.

Closure of admissions.

As per NMC/DCI schedule

Candidates must register online and upload scanned original certificates on the website In addition, the candidates will have to take a printout of the Prospectus/Instructions to fill the application form from the website or before proceeding to fill the application form.

The registration and processing fee is Rs.3500 (Bank transaction charges extra) for OC & BC candidates, and for SC/ST candidates is Rs.2900 (Bank transaction charges extra). The fee shall be paid online through a Debit card / Credit card or Net Banking.

Once paid, the verification and registration fee will not be refunded or adjusted to a future date. Therefore candidates are advised to check eligibility conditions thoroughly before applying for determining state merit positions in respective categories for Competent Authority Quota seats using NEET-UG rank.

Steps to register for the UG admission program –

1. Mobile and Email Registration

2. Candidate Registration (Payment of fee)

3. Updating of data

4. Uploading of Certificates

The provisional final merit position of the applied candidates will be prepared based on NEET UG - 2022 rank and other eligibility criteria notified here after verification of original scanned certificates. Final verification of original certificates will be conducted at the time of admission at the allotted college by Admission Committee.

The documents required –

1. NEET UG Rank Card. (Mandatory)

2. Birth Certificate (SSC Marks Memo). (Mandatory)

3. Qualifying test Certificate (Intermediate Marks Memo OR Equivalent – Grade Certificate not Accepted) (Mandatory)

4. Study Certificates from 6th to 10th (If More than one certificate, scan all into a single PDF file) (Mandatory)

5. Study Certificates - Intermediate or equivalent for 2 Years (If More than one certificate, scan all into a single PDF file) (Mandatory)

6. Transfer Certificate

7. Latest Caste Certificate (Mandatory) If applicable) with father name

8. Minority Certificate (Muslim Only) (Mandatory) If applicable)

9. EWS Certificate for the year 2022-23 claiming reservation under EWS Categories issued by Competent Authority (Tahasildar) of State of Telangana (Mandatory) If applicable)

10. Latest Parental Income Certificate (If applicable)

11. NCC Certificate (If More than one certificate, scan all into a single PDF file) (Mandatory) If applicable)

12. CAP Certificate (If More than one certificate, scan all into a single PDF file) (Mandatory) If applicable)

13. PMC Certificate (Mandatory) If applicable)

14. Anglo-Indian Certificate (Mandatory) If applicable)

15. Residence certificate of the candidate or either parent issued by MRO / Tahasildar of Telangana/AP for a period of ten - years (Period to be specified with exact month and year) excluding the period of study/employment outside the state. (Mandatory) If applicable)

16. Employment certificate of parent (For Non-Local Status) if applicable

17. Aadhar Card

18. Candidate's Latest passport-size Photo (Mandatory)

19. Specimen Signature of the Candidate (Mandatory)

Seats –

1. The number of MBBS/BDS seats for the academic year 2022-2023 at Government Medical / Dental Colleges and Private Medical / Dental Colleges will be as permitted by NMC/DCI and notified before counselling. Tuition Fees will be as notified by the State Government.

2. The seat matrix for Competent Authority Quota seats for the academic year, i.e., 2022- 23, will be displayed on the KNRUHS website before exercising web options for counselling.

3. If NMC/DCI permits any new MBBS/BDS seats in colleges affiliated with the University for the Academic Year 2022-2023, those seats will also be filled up.

Eligibility –

1. The candidate shall be an Indian Nationals (citizen of India). Candidates who satisfy the Local or Non- local status in Telangana (Residence requirement) as laid down in Andhra Pradesh Education Institutions (Regulations of Admissions) Order, 1974 only are eligible to apply for MBBS/BDS admissions.

2. Candidate should have passed Intermediate (10+2 pattern) or equivalent examination with Physics, Chemistry, Biology (Botany, Zoology) / Biotechnology and English.

3. OC candidates seeking EWS reservation should obtain not less than 50% marks in science subjects.

4. BC/SC/ST candidates should obtain not less than 40% marks in science subjects.

5. OC PWD candidates should obtain not less than 45% marks in science subjects.

6. Candidate should have completed 17 years of age as of 31-12- 2022.

7. Candidates shall secure the following cutoff scores or above in the National Eligibility- cum- Entrance Test (NEET) UG -2022, conducted by CBSE, New Delhi, as per section (10) of the Indian Medical Council Act, 1956.

Eligibility conditions for candidates who are domiciled in Telangana /Andhra Pradesh – The candidate shall satisfy Local / Non-local status as per GO.No.646 Education (W1) department dated 10-07-1979 and Presidential order.

Non-local candidates are eligible for 15% of unreserved seats only. The local candidates are also eligible for 15% unreserved seats along with 85% seats reserved for the local area. Candidates who are domiciled in other States do not qualify unless they satisfy one of the conditions mentioned below to be eligible for admission under the unreserved quota.

Important information for candidates –

1. Online application form without uploading mandatory Certificates, Passport size photo, without a signature at the declaration area, incomplete applications will be automatically rejected and will not be considered for determining the Merit position in respective categories using NEET-UG-2022 Rank.

2. The mere fact that a merit position is issued to the candidate does not imply that the University accepts the candidature and does not mean that the entries made by the candidate in the online application are accepted as true and correct.

3. University will take up the verification of certificates about eligibility conditions, i.e., educational qualifications, Local/Non-Local area status, and category status as per uploaded relevant certificates by the concerned department officials. If the information furnished by the candidate in the application is incorrect, their candidature is liable to be cancelled, and further action that is deemed fit will be taken.

4. Candidates' eligibility for admission into UG courses for the academic year 2022-2023 will be examined by the University only after scrutiny of the application along with all uploaded copies of required certificates, and a provisional final merit list will be notified.

5. Registration and uploading Scanned Original certificates will be done only once, irrespective of the number of counselling. No separate notification will be issued for verification of original certificates. Therefore the candidates should register and upload all the mandatory Certificates without fail.

6. An in-eligible candidate obtaining a Merit position does not make the candidate eligible for admission. Admission will be considered only for candidates who have secured marks above the cutoff score in NEET- UG-2022 test and based on the state merit order, as the case may be.

7. The University and concerned departmental officials shall conduct scrutiny of uploaded Original Certificates. After scrutiny of the application and certificates provisional final merit list will be released.

8. Candidates have to exercise web options for seats in the colleges in which there are interested in joining for the MBBS course and BDS course separately.

9. After allotment, the candidate should get the allotment order, submit the printout of the filled-in Online application form, allotment order, Bonds and original certificates along with (1) a set of self-attested copies to the Principal of the allotted college at the time of joining for final verification by the admissions committee of the allotted college. The Admission Committee is responsible for scrutiny of the original certificates submitted by the candidate. In case of any discrepancy, the provisional allotment order for admission will be cancelled.

10. Candidates must pay the University fee of Rs.12000 through a payment gate and obtain the allotment letter.

11. Tuition Fee will be as notified by the Government of Telangana.

12. Candidates cannot discontinue the course after being notified cutoff date for discontinuation or later. Candidates will have to submit a bond for the same. Candidates shall pay the Bond amount of Rs. 2000000 if they discontinue the course after the last date of free exit.

13. The admissions shall be closed per the schedule the University notified as per MCI/NMC Regulations.

14. The course shall commence as per the schedule notified by National Medical Commission. The duration of the system shall be calculated from the date of commencement of the course and shall be uniform for all the candidates irrespective of individual dates of admission.

To view the notices, click on the links below -

Tue, 11 Oct 2022 18:15:00 -0500 en text/html
Killexams : King County doctor files to have medical suspension lifted

A King County doctor who had her license summarily suspended by the Washington Medical Commission (WMC) has met the deadline to potentially have that suspension lifted.

The WMC said Dr. Kristine Brecht requested a show-cause hearing last week. A show-cause hearing is held when a party wants to justify or explain why the court should or should not grant a motion, and in Brecht's case, that motion would be the suspension lifted. 

The Burien-based doctor had her license suspended following allegations that she violated an agreement that placed restrictions on her ability to practice.

Brecht is licensed in family medicine and does not have a license for plastic surgery.

Since our first report, former patient Stephanie Kodis-Fisher reached out to FOX 13 to share what happened to her.

Kodis-Fisher said Brecht performed an arm lift and tummy tuck on her in one operation in 2020.

"I was appalled and embarrassed for myself and thinking for anyone else who may have gone after me," said Kodis-Fisher.

She noticed red flags when she said Brecht told her to take a powerful combination of drugs on the day of her surgery.

"She told me to take Ambien and Oxycodone and Arnica," said Kodis-Fisher.

"I remember waking up partially through the surgery and I remember them saying ‘here, take another pill,’" said Kodis-Fisher.

Last July, Brecht agreed to significant restrictions on her practice, including no longer performing surgeries requiring anesthesia.
The Washington Medical Commission says they summarily suspended Brecht after she violated this agreement earlier this spring on at least 10 occasions.

"In the field of cosmetic surgery, one of the tricky things is a lot of it is done in small clinics," said Dr. Hakim Said, a board-certified plastic surgeon in Seattle. 

He said cosmetic surgeries can be a gray area in our country. 

"Seattle is not the worst place for this, but in other places where it's well regulated, like in Canada, this problem doesn't happen," said Dr. Said.

He urges anyone considering cosmetic surgery to research doctors on the American Board of Medical Specialties site.

"Certification Matters is the website that will tell you if the provider you're considering is actually trained and certified to do the surgery that you're considering," said Dr. Said.

Kodis-Fisher says she did get a referral for Dr. Brecht, but wishes she had dug a little deeper into her background.

"Don't let doctors wow you with their paperwork and their websites and their words," said Kodis-Fisher.

Though it's been nearly three years since her operation with Brecht, she says she is still in pain and her arms have not fully recovered. She also has physical scars on her arms. 

"I don't go out in public with short sleeves anymore, my students ask me what's wrong with my arms constantly and it's just embarrassing," said Kodis-Fisher.

While Brecht hasn't lost her license, the Washington Medical Commission says "…at this juncture, Dr. Brecht is legally barred from doing ANY type of medical procedure regardless of what type of sedation is used."

The Washington Medical Commission advises anyone to file a complaint if they experience a negative outcome due to a breach of UDA standards.

Meanwhile, Brecht is still actively posting on her Facebook page, offering consultations to explain cosmetic procedures that can be done while awake.

FOX 13 reached out to Dr. Brecht multiple times since her last suspension order. She told us she would get back to us with what she considers the truth, but has yet to respond to our recent request.

Her show-cause hearing is scheduled for Oct. 20. 

Mon, 10 Oct 2022 23:50:00 -0500 en text/html
Killexams : MBBS books in local languages soon, NMC to take lead role

Express News Service

NEW DELHI: Madhya Pradesh may be the first state to roll out textbooks in Hindi for medical students, but medicine will soon be taught in the country in regional languages as well. The High Powered Committee for Promotion of Indian Languages under the Ministry of Education has already initiated dialogues with the National Medical Commission (NMC), state medical councils, medical universities and colleges and also doctors and professors, on preparing medical syllabus in Hindi and other regional languages, Chamu Krishna Shastry, the committee’s chairman, told this newspaper.

Shastry said that the Tamil Nadu Dr MGR Medical University Vice Chancellor, Dr Sudha Seshayyan M.S., has already started preparing a glossary on medical terms in Tamil.  He added that Home Minister Amit Shah will release the country’s first MBBS syllabus in Hindi for students on October 16. Hopefully, other states will follow suit, he said.

“They (MP) have prepared textbooks for first-year MBBS students. They are working on preparing the rest of the medical course books. The main aim is to bring medical textbooks in Hindi and other regional languages,” Shastry added. While teaching in English will continue, students will have the option to study both  in Hindi and their regional language.

The idea behind the initiative is that 90 per cent of patients don’t know English. “A large section of the students also come after having studied in their mother tongue, and all of a sudden, when they start medical education in English medium they find it difficult to comprehend medical language,” Shastry added.

“Students from rural areas would like to work in their hometowns or villages. So we will be able to create a workforce catering to rural healthcare facilities. The quality of the books won’t be compromised,” Shastry said. 

However, the plan has drawn flak from the medical fraternity. Dr Rohan Krishnan, president, FAIMA Doctors Association, said that it will affect the students adversely. “Medical education needs to be at par with international guidelines and bodies,” he said, adding that students will get confused and the quality will fall.

Dr Furquan Ahmad, former joint secretary of Resident Doctors Association, RML, tweeted, “Teaching MBBS in Hindi is a regressive step. Hyper Nationalism is the root cause. Tomorrow, they will demand to launch it in Sanskrit, but what’s the point of writing English words in Devnagari script for political agenda? NMC is a complete failure.” 

Dr Manish Jangra, FAIMA founding member, said doctors, after completion, will find themselves unfamiliar with guidelines and will have to depend on poor salaries.

Fri, 14 Oct 2022 14:43:00 -0500 text/html
Killexams : Mental Health Issues Among Medical Students: Colleges To Submit Report Of Suicides, Drop-Outs To NMC Today No result found, try new keyword!Commission has asked medical colleges to submit the details latest by October 7. The move comes after a rise in incidents of suicides and overwork among medical students Amid the rise of suicide ... Thu, 06 Oct 2022 19:56:00 -0500 text/html Killexams : Huntsville planning commission takes first steps towards medical marijuana dispensaries

Updated: 1 hour ago

There's a chill in the air now, but temperatures will gradually warm into the 70's by the weekend.

Updated: 3 hours ago

Moline dog and owner co-author a book on how to beat cancer

Updated: 9 hours ago

The Salvation Army’s annual Project Bundle Up is partnered with KWQC for another drive at the station to collect winter clothing items for kids in need this winter.

Wed, 12 Oct 2022 11:38:00 -0500 en text/html

Ninth Edition of Amgen's Biosimilar Trends Report Examines the U.S. and Global Marketplace with Biosimilars

THOUSAND OAKS, Calif., Oct. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today released the 9th edition of its Biosimilar Trends Report, which examines the current and future state of the U.S. marketplace with biosimilars. This year, in addition to examining important trends in the U.S., the Report also highlights key considerations and learnings from the global marketplace with biosimilars. To access the full Report, visit

"Our 2022 Biosimilar Trends Report found that the marketplace with biosimilars is well established, and the U.S. is poised to see continued growth in biosimilar approvals. This is good news for patients, physicians and payers, as the successful adoption of biosimilars has increased competition and generally lowered treatment costs associated with biologic medicines," said Jen Norton, vice president and head of U.S. Value & Access at Amgen.

New data from the Report confirm that biosimilar uptake in the U.S. continues to increase over time, resulting in significant market share in most therapeutic areas where biosimilars have been introduced. In fact, for therapeutic areas that have had biosimilars launch in the last three years, the average biosimilar sharewas 75 percent compared to 39 percent in the preceding three years.1 

"The trends highlighted in the Report underscore that it's an exciting time for the marketplace with biosimilars. As biosimilars become more widely available in the U.S., they have the potential to help to control costs for patients, payers and health systems," said Chelsee Jensen, pharmaceutical formulary manager at the Mayo Clinic.

The Report also discusses biosimilars' potential to expand access to treatment options that may lower healthcare costs.2 In particular, the Report found:

  • Trends show an increase in savings per quarter, and in Q2 alone, savings in drug spend due to biosimilar availability are estimated to be $3.2 billion.3
  • Biosimilars primarily covered under the medical benefit have typically launched at a wholesale acquisition cost (WAC) that is generally 10% to 57% lower than that of the reference product.4
  • There are currently seven FDA-approved biosimilars for the reference product HUMIRA, with the possibility of seven or more launches in 2023. The entry of biosimilars is expected to lead to price declines across all products within the class.5

"Biosimilars are another potential treatment option for the millions of Americans living with inflammatory-bowel disease (IBD)," said Laura Wingate, executive vice president, Education, Support & Advocacy, Crohn's & Colitis Foundation. "We are excited about the potential expansion of biosimilars in the U.S. as we know how important it is for patients to have a variety of options." 

About Amgen Biosimilars
Amgen is committed to building upon Amgen's experience in the development and manufacturing of innovative human therapeutics to expand Amgen's reach to patients with serious illnesses. Biosimilars help to maintain Amgen's commitment to connect patients with vital medicines, and Amgen is well positioned to leverage its nearly four decades of experience in biotechnology to create high-quality biosimilars and reliably supply them to patients worldwide.

For more information, visit

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. 

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that Improve health outcomes and dramatically Improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. 

Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index.  In 2021, Amgen was named one of the 25 World's Best Workplaces™ by Fortune and Great Place to Work™ and one of the 100 most sustainable companies in the world by Barron's.

For more information, visit and follow us on

Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd., Kyowa-Kirin Co., Ltd.,  or any collaboration to manufacture therapeutic antibodies against COVID-19), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), the Five Prime Therapeutics, Inc. acquisition, the Teneobio, Inc. acquisition, or the recently announced proposed acquisition of ChemoCentryx, Inc., as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and real results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.

Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no certain that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. 

CONTACT: Amgen, Thousand Oaks 
Kelley Davenport, 202-834-8347 (media)
Jessica Akopyan, 805-440-5721 (media)
Arvind Sood, 805-447-1060 (investors) 

1 Data on file, Amgen; Biosimilar Market Share Trends; July 2022.
2 IQVIA (2018). The Impact of Biosimilar Competition in Europe. PDF file. Retrieved from:
3 Data on file, Amgen; Biosimilars Spend Analysis; July 2022.
4 Data on file, Amgen; Reference Product and Biosimilars - WAC and ASP Price; July 2022.
5 Xcenda (2022). Biosimilar approval and launch status in US. Retrieved from:


Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)


Cision View original content to get multimedia:


Wed, 12 Oct 2022 01:07:00 -0500 en text/html
Killexams : Countrywide medical colleges’ entry test on Nov 13

ISLAMABAD: Pakistan Medical Commission (PMC) President Prof Dr Noshad Ahmad Shaikh on Monday said Medical and Dental Colleges Admission Test (MDCAT) would be held on November 13 throughout the country.

Speaking at a press conference, Dr Shaikh said 210,000 candidates had applied for MDCAT for 20,800 seats in medical and dental colleges.

He said after appointment by the prime minister, the new nine-member PMC council assumed the charge on Sept 7 and took a number of steps to resolve genuine and relevant issues of doctors, students and relevant stakeholders.

He said Bolan University of Medical and Health Sciences will hold the test in Balochistan, University of Health Services in Punjab, Khyber Medical University in Khyber Pakhtunkhwa, Dow University of Health Sciences in Sindh and Shaheed Zulfikar Ali Bhutto Medical University will hold the test for the students of Islamabad, Azad Kashmir and Gilgit-Baltistan.

Varsities in provinces to decide whether to conduct MDCAT themselves or through testing agency, says PMC

“All vice chancellors of the public universities and concerned stakeholders were taken on board to decide the conduct of MDCAT through meetings in every province. The universities will decide on the modalities of conducting the test i.e. either by themselves or through a testing agency,” he said.

He said the National University of Medical Sciences (Nums) will hold the test for its constituent and affiliated medical and dental colleges. Nums’ MDCAT would be under the umbrella of PMC and shall only be valid for admission to Nums’ constituent and affiliated colleges.

The PMC president said the pass percentage in MDCAT for admission to MBBS will be 55pc and for BDS 45pc. Moreover, students with FSc (pre-medical) or equivalent with 60pc marks will be eligible to apply for admission to the colleges.

“MDCAT will be paper based manual test and the answer keys of the papers will be uploaded by the concerned universities on the PMC website the same day after the exam,” he said.

Dr Noshad said in Punjab the centres for MDCAT would be established in Lahore, Gujranwala, Sialkot, Faisalabad, Sahiwal, Multan, Bahawalpur and Dera Ghazi Khan while in Sindh the centres would be in Karachi, Hyderabad, Nawabshah and Khairpur. In Khyber Pakhtunkhwa, Abbottabad, Peshawar, Swat and Dera Ismail Khan would have centres while in Balochistan MDCAT centre would be in Quetta.

In Gilgit-Baltistan, the centre will be established in Gilgit and in Mirpur and Muzaffarabad in Azad Kashmir. A centre will also be set up in Islamabad.

He also said the council had decided to conduct MDCAT in UAE and Saudi Arabia due to the maximum number of students in these countries. Candidates in other countries may either change their centres to UAE and Saudi Arabia or come to Pakistan for the exam.

He said the council had also decided that the National Licensing test (NLE) test for local students shall be conducted through their degree-awarding universities under the umbrella of PMC. Pass percentage for NLE 1 and NLE 2 has been reduced from 70 to 50 but it would not be used as a retrospective.

Talking about the World Federation for Medical Education (WFME), he said the PMC had qualified the eligibility for it.

“A task force has been constituted to sum up the work that has been done so far along with proposed steps for the WFME accreditation. The task force will expedite the finalisation of the accreditation application to be submitted to the WFME before the deadline of 2024 fixed by Educational Commission for Foreign Medical Graduates (ECFMG).

The council has decided that inspection of medical and dental colleges shall be carried out by the PMC, he said.

Dr Noshad said renewal of doctors’ registration certificates had been extended from two years to five years.

“Senior doctors who are 60 years and above shall renew their registration certificate and will have to pay 50pc of the total fee,” he added.

Published in Dawn, October 11th, 2022

Mon, 10 Oct 2022 14:33:00 -0500 en text/html
Killexams : Dairy Testing Services Market Size 2022 COVID-19 Impact on Revenue of Best Industry Players by 2032

The global dairy testing services market is expected to witness growth at a CAGR of 8.1% in the forecasted period and to be valued more than USD 7.3 Bn by 2032.

Pesticides, viruses, toxins, and heavy metals are the most common causes of foodborne diseases. According to a 2019 WHO estimate, over 23 million people in Europe become unwell after eating tainted food, with 4,700 people dying each year. Raw and unpasteurized milk, cheese, and ice cream are the most common sources of contamination in dairy products all over the world. If raw milk is handled incorrectly before or after pasteurisation, pathogenic contamination can develop.

Get a sample PDF of report @

Moreover, Cronobacter, Enterobacteriaceae, and Salmonella must be absent in dried infant formula and dried dietary meals for specific medical purposes intended for children under six months of age in the EU, according to Commission Regulation (EC) No. 2073/2005.This food must also be tested for the presence of Bacillus cereus, which is suspected.

In the United States, all finished dry product infant formula samples (domestic or imported) that have to be tested for Salmonella and Cronobacter must be examined. Each sample for Salmonella analysis should be 25 grammes or larger, and for Cronobacter analysis, it should be 10 grammes or larger.

Key Takeaways from Market Study

  • The dairy testing services market is expected to expand at CAGR of 8.1% over the forecasted period.
  • Among the testing type segment, safety testing is dominating the segment holding around 51.3% of the revenue and it is expected to grow with CAGR of 5.6% over the forecasted period.
  • Among the technology, traditional segment is expected to dominate the technology segment holding more than 43.6% revenue share and it is expected to grow with around 6.8% CAGR over the forecast period.
  • Raw milk is dominating the product type segment holding around 28.7% in 2022 and it is expected to grow with CAGR of 4.6% over the forecasted period.

"Dairy Products are in high demand around the world as they provide, multiple health benefits like sustain energy, gut health, immunity boosting, calming. Manufacturers are spending high amount of money on R&D in order to develop innovative dairy products. Manufacturers are introducing a variety of new milk products." says a Future Market Insights analyst.

Make an Enquiry before Buying@

Competitive Landscape

Key manufacturers of dairy testing services market are majorly focusing on research & development in order to develop innovative and unique product offering. In addition to this these key players in the dairy testing services market are also concentrating on merger, acquisition and joint ventures to expand their geographical presence and also to increase the existing production capacity.

  • SGS S.A bought IDEA TESTS in October 2021. IDEA is based in Talence (Bordeaux area), Plouzane and Martillac (Brest region) in France, as well as Bucharest, Romania. In 2020, IDEA employed about 80 people and generated approximately EUR 6 million in revenue.

Key Companies Profiled in Dairy Testing Services Market are SGS SA, Eurofins Scientific, Merieux Nutrisciences, ALS Limited, Bureau Veritas, TUV Nord Group, AsureQuality Limited, Intertek Group plc, Microbac Laboratories, Neogen Corp.

Dairy Testing Services Market by Category

By Testing Type, Dairy Testing Services Market is segmented as:

  • Safety Testing
    • Pathogens
      • Cronobacter sakazakii
      • E. Coli
      • Salmonella
      • Campylobacter
      • Listeria
      • Others (Others include vibrio, clostridium, staphylococcus, and bacillus)
    • Pesticides
    • Mycotoxins
    • Adulterants
    • Genetically Modified Organisms (GMOS)
  • Quality Testing

By Technology, Dairy Testing Services Market is segmented as:

  • Traditional
  • Rapid Testing
    • Convenience-Based
    • Immunoassay
    • Chromatography & Spectrometry
    • Polymerase Chain Reaction (PCR)

By Product Type, Dairy Testing Services Market is segmented as:

  • Raw Milk
  • Pasteurized Milk/Modified Milk
  • Cheese and Processed Cheese
  • Infant Formula
  • Milk Powder
  • Fermented Milk
  • Others (Cream, Deeps, Dressings)

Ask for Report Customization@

Frequently Asked Questions

  • How much is Dairy Testing Services Market worth?
  • What is the North America Dairy Testing Services Market?
  • Who are the key players involved in the dairy Testing Services market?
  • How Much Does Food Industry contribute to the Dairy Testing Services market?
  • At What Rate Will Dairy Testing Services Demand Grow in China?

Explore FMI's related ongoing Coverage on Food and Beverage Domain

Dairy Alternatives Market: Dairy Alternatives Market value is expected to reach US$ 123,634.7 Mn by 2032, rising at a CAGR of 14.7% for 2022-32.

Dairy Processing Equipment Market: Dairy Processing Equipment Market is expected to grow at a CAGR of 5.4% during the forecast period (2022-2032).

Download complimentary copy of Future Market Insights White Paper in collaboration with PBFIA, on the Plant Based Market that throws light on potential opportunities and investments made in the Global plant based market

About FMI

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.


Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware - 19713, USA

T: +1-845-579-5705

For Sales Enquiries:

Browse Other Reports:

LinkedIn| Twitter| Blogs

The post Dairy Testing Services Market Size 2022 COVID-19 Impact on Revenue of Best Industry Players by 2032 appeared first on Future Market Insights.

Original Source of the original story >> Dairy Testing Services Market Size 2022 COVID-19 Impact on Revenue of Best Industry Players by 2032

This content is published on behalf of the above source. Please contact them directly for any concern related to the above.

This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that real results may differ materially from those projected in the forward-looking statements.

Wed, 12 Oct 2022 09:02:00 -0500 en text/html
CGFNS exam dump and training guide direct download
Training Exams List